Bristol-Myers Squibb
FDA Approves Neoadjuvant/Adjuvant Opdivo for Resectable NSCLC
The FDA approved Opdivo with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent ...
OCTOBER 4, 2024
FDA Grants New Indication for Opdivo + Yervoy Combo in mCRC
The FDA granted a new indication for Opdivo and Yervoy to treat adults and children 12 years of age and older with ...
JULY 12, 2018
Investigational Drug Stops Serious Bleeds in Patients Taking Factor Xa Inhibitors
About 84,000 patients taking factor Xa inhibitors are hospitalized for major bleeding each year.
MARCH 15, 2018
Teva Launches Generic Version of Reyataz
Generic atazanavir sulfate capsules are a protease inhibitor (PI) used in combination with other ART for the ...
DECEMBER 28, 2017
FDA Grants Opdivo New Indication for HCC Patients Previously Treated With Sorafenib
The U.S. burden of hepatocellular carcinoma is significant. A recent ACS report noted that death rates from liver ...
OCTOBER 2, 2017
Opdivo Receives New Indication for MSI-H or dMMR Colorectal Cancer
The FDA granted a new indication to Opdivo for the treatment of patients aged 12 years and older with mismatch ...
AUGUST 2, 2017